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Mixed lineage kinase domain-like (MLKL) is a
component of the ‘‘necrosome,’’ the multiprotein
complex that triggers tumor necrosis factor (TNF)-
induced cell death by necroptosis. To define the
specific role and molecular mechanism of MLKL
action, we generated MLKL-deficient mice and
solved the crystal structure of MLKL. Although
MLKL-deficient mice were viable and displayed no
hematopoietic anomalies or other obvious pathol-
ogy, cells derived from these animals were resistant
to TNF-induced necroptosis unless MLKL expres-
sion was restored. Structurally, MLKL comprises a
four-helical bundle tethered to the pseudokinase
domain, which contains an unusual pseudoactive
site. Although the pseudokinase domain binds
ATP, it is catalytically inactive and its essential
nonenzymatic role in necroptotic signaling is in-
duced by receptor-interacting serine-threonine
kinase 3 (RIPK3)-mediated phosphorylation. Struc-
ture-guided mutation of the MLKL pseudoactive
site resulted in constitutive, RIPK3-independent
necroptosis, demonstrating that modification of
MLKL is essential for propagation of the necroptosis
pathway downstream of RIPK3.
INTRODUCTION
Caspases, activated on oligomeric platforms or by proteolytic
cleavage, are the effector molecules of apoptosis, cleaving
hundreds of cellular proteins, thereby resulting in cellular
dismantling and characteristic apoptotic morphology. In
contrast, programmed necrosis, or necroptosis, occurs when
apoptosis and caspase activity are inhibited and is thought to
provide an important defense against intracellular pathogens
that can suppress classical apoptotic cell death (VandenabeeleImet al., 2010; Vanlangenakker et al., 2012). Cytotoxic stimuli,
such as tumor necrosis factor receptor 1 (TNFR1) ligation,
trigger the assembly of intracellular complexes that activate
prosurvival and inflammatory NF-kB and MAPK signaling path-
ways (Wertz and Dixit, 2010), but they can also activate cas-
pase-8. In most situations prosurvival signaling from TNFR1,
in particular NF-kB-mediated transcriptional upregulation of
the caspase-8 inhibitor cFLIP, inhibits apoptosis (Micheau
et al., 2001). However, when NF-kB is inhibited or TNFR1
signaling is otherwise impaired, caspase-8 becomes activated
and causes cell death by apoptosis. Active caspase-8 can
also cleave and thereby inhibit the receptor interacting serine-
threonine protein kinase 1 and 3 (RIPK1 and RIPK3), thus
blocking the necroptotic pathway. When caspase-8 is inhibited,
for example by the viral FLIP-like proteins or by the synthetic
caspase inhibitor QVD-OPH, TNFR1-induced apoptosis is in-
hibited, but the brake on the necroptotic pathway is also
removed, allowing TNF to kill cells by necroptosis. Other pro-
teins that influence the sensitivity of cells to necroptosis include
cellular inhibitor of apoptosis proteins (cIAPs), which ubiquity-
late and thereby inactivate RIP kinases, and deubiquitylating
enzymes (DUBs), which deubiquitylate and thus activate RIP ki-
nases (Vandenabeele et al., 2010). Experiments with gene-tar-
geted mice have shown that the RIP kinases RIPK1 and RIPK3
are essential for TNF-induced necroptosis, and studies with
RNAi-mediated knockdown or chemical inhibitors have also
implicated the pseudokinase, mixed lineage kinase domain-
like (MLKL), in this process (Sun et al., 2012; Wang et al.,
2012; Zhao et al., 2012). However, the mechanism by which
RIP kinases drive necroptosis, and the role of MLKL in this pro-
cess, remain unclear.
MLKL is classified as a ‘‘pseudokinase’’ because its kinase-
like domain lacks two of the three conserved catalytic residues
considered crucial for phosphoryl transfer activity (Manning
et al., 2002). Protein kinases rely on the Lys of the Val-Ala-Ile-
Lys (VAIK) motif for interaction with the a and b phosphates of
ATP to position ATP during phosphotransfer; on the Asp of the
His-Arg-Asp (HRD) motif within the catalytic loop (subdomain
VIb) to act as a catalytic residue; and on the Asp within the
Asp-Phe-Gly (DFG) motif in the activation loop (subdomain VII)munity 39, 443–453, September 19, 2013 ª2013 Elsevier Inc. 443
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Figure 1. Structure of Mouse MLKL
(A) The structure of MLKL reveals an N-terminal
helical bundle (magenta), a two-helix brace or
linker (cyan), and a C-terminal pseudokinase
domain (green). The activation loop helix, which
forms part of the pseudokinase domain N-lobe, is
colored in blue.
(B) Close-up of the pseudoactive site of MLKL
reveals unusual coordination geometry for K219 in
the VAIK motif. Instead of the classical kinase
interaction with E239 of helix aC, it interacts with
Q343 located on the atypical activation loop helix
that occupies the canonical helix aC position.
Other residues labeled correspond to deviations
from residues typical for ATP binding and phos-
pho-transfer in active protein kinases: G336 in
MLKL replaces the Asp in the DFG motif respon-
sible for Mg2+ coordination; N318 in MLKL re-
places Asp of the HRD motif in the catalytic loop;
and S323 that replaces the typical Asn located five
residues C-terminal to the HRD motif usually
involved in Mg2+ coordination.
(C) The pseudoactive site of MLKL overlaid with
side chains of key residues within the active site of
PKA (pdb 1ATP) (Zheng et al., 1993). Side chains
for equivalent PKA residues to those described for MLKL are displayed in yellow, ATP is displayed in magenta, and Mn2+ (used in this structure as a surrogate for
Mg2+) displayed as spheres.
In all cases, oxygen atoms are displayed as red, nitrogen atoms as blue, and phosphorus atoms as orange. See also Figure S1 and Tables S1 and S2.
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(Hanks et al., 1988). In MLKL orthologs in chordate species,
the VAIK motif is highly conserved but the HRD motif is absent
and the DFG motif is degenerate and almost universally
conserved as GFE. Pseudokinases comprise 10% of mamma-
lian kinomes and have emerged as regulators of cell signaling,
acting predominantly as modulators of bona fide protein kinases
(Boudeau et al., 2006; Saharinen and Silvennoinen, 2002; Zeqiraj
and van Aalten, 2010). In some instances, pseudokinase
domains, for example HER3 (Shi et al., 2010) and JAK2 (Ungur-
eanu et al., 2011), have been observed to possess limited cata-
lytic activity, although the generality of this phenomenon remains
unclear (Eyers and Murphy, 2013).
We determined the crystal structure of full-length MLKL to
2.6 A˚ resolution revealing a four-helical bundle tethered to the
pseudokinase domain. Generation of MLKL-deficient mice re-
vealed that whereas under stress-free conditions, these animals
are healthy, fertile, and ostensibly normal, cells derived from
them were resistant to TNF-induced necroptotic cell death.
We used MLKL-deficient cells reconstituted with inducible
MLKL expression constructs to test the functional conse-
quences of structure-guided mutations in MLKL. Mutations
within the pseudoactive site of the pseudokinase induced
constitutive necroptosis in the absence of TNF or other cytotoxic
stimuli. These MLKL mutants were also constitutively active in
Ripk3/ fibroblasts. This illustrates that these mutants circum-
vent the requirement of RIPK3-mediated phosphorylation for
activation and place RIPK3 upstream of MLKL in the necroptotic
signaling pathway. Furthermore, the mitochondrial effector
PGAM5 (Wang et al., 2012) did not appear to be necessary for
necroptosis, suggesting that additional or alternative effectors
must operate downstream of MLKL to induce necroptotic cell
death.444 Immunity 39, 443–453, September 19, 2013 ª2013 Elsevier Inc.RESULTS
MLKL Comprises an N-Terminal Four-Helix Bundle
Tethered to the C-Terminal Pseudokinase Domain
The crystal structure of full-length murine MLKL was determined
by X-ray diffraction at a resolution of 2.6 A˚. The structure
revealed that the N-terminal domain (amino acid residues 1 to
170) consists of a four-helix bundle followed by a two helix linker,
or brace, connecting the bundle to the pseudokinase domain
(residues 171 to 464, Figure 1A; crystallographic statistics in Ta-
ble S1 available online). Additional studies with small-angle X-ray
scattering confirmed that this unusual arrangement of domains
is representative of MLKL in solution and not just within the crys-
tal (Figures S1A–S1C; Table S2).
The C-terminal region of MLKL adopts a typical kinase-like
fold, comprised of a smaller N-lobe made up of five antiparallel
b strands and the helix aC and of the larger C-lobe composed
principally of a helices. MLKL is classified as a pseudokinase
based on the absence of Asp in the HRD motif of the catalytic
loop and the absence of Asp in the DFG motif responsible for
Mg2+ coordination (Figure S1D). Although the Lys within the
ATP-binding VAIK sequence is conserved in MLKL, the structure
reveals unusual coordination geometry for this residue (Fig-
ure 1B). Typically, in active protein kinases, this conserved Lys
is positioned by a conserved Glu (E91 in cAMP-dependent pro-
tein kinase, PKA; E239 in MLKL) present on helix aC (Huse and
Kuriyan, 2002; Taylor et al., 2012). However, inMLKL, the canon-
ical helix aC position is occupied by an atypical a helix formed by
theN-terminal segment of theMLKL activation loop (or ‘‘A-loop’’)
comprising S340-I346 (colored blue in Figures 1A–1C). The acti-
vation loop of protein kinases is positioned in the cleft between
the N- and C-lobes and begins after the canonical DFG motif
in the N-lobe and extends into the C-lobe, providing a platform
Immunity
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loops of protein kinases are typically very mobile, consistent
with an absence of electron density for the residues K351-
S358 in our MLKL structure. The MLKL activation loop helix
occupies the position normally held by helix aC in conventional
protein kinases and contributes Q343 to positioning the ATP
binding lysine of the VAIK motif, in place of the helix aC gluta-
mate typical of conventional kinases (Figure 1B). Despite this
unusual arrangement, the ATP binding pocket is largely unaf-
fected. A comparison between MLKL and PKA suggests that
this pocket within MLKL should still be sufficiently large to
accommodate ATP with minimal conformational rearrange-
ments required (Figure 1C). Nevertheless, the absence of HRD
and DFG motifs suggests that any such binding is unlikely to
be catalytically productive; thus we refer to the cleft between
the pseudokinase domain N- andC-lobes as the ‘‘pseudoactive’’
site in MLKL.
MLKL Binds ATP but Is a Catalytically Inactive Substrate
of RIPK3
N-terminally His6-tagged MLKL pseudokinase domain was
expressed in insect cells and the recombinant protein purified
by Ni2+-affinity and size exclusion chromatography. Its ability
to bind ATP, ADP, AMP, and the ATP analog AMPPNP in the
presence or absence of Mg2+ or Mn2+ ions was tested in thermal
stability shift assays. In these assays, ligand binding confers
thermal stability to the protein, resulting in an increase in the
melting temperature that can be measured by means of the
dye Sypro Orange, which fluoresces upon binding to the hydro-
phobic surfaces exposed during protein denaturation (Lo et al.,
2004; Lucet et al., 2013). Consistent with our prediction from
the structure, we observed that wild-type MLKL bound ATP,
ADP, and AMPPNP, but only in the absence of cations (Figures
2A and 2B). This binding was specific, because a mutant form
of MLKL, in which the canonical ATP-binding lysine within the
VTIK219 motif in the b3 strand was mutated to methionine
(K219M), did not bind these ligands (Figures 2C and S2A). These
data demonstrate that ATP binding occurs in the conventional
ATP binding cleft between the MLKL pseudokinase N- and
C-lobes. However, these data also suggest that MLKL is unlikely
to function as a catalytically active protein kinase, because Mg2+
(or Mn2+) is known to play an essential role in the phosphoryl
transfer mechanism of protein kinases.
The active sites of conventional, catalytically active protein
kinases utilize an ion pair between the lysine of the VAIK motif
and a glutamate in the helix aC to position the lysine for interac-
tion with the a- and b-phosphates of ATP during catalysis. In
contrast, in MLKL, K219 of the VTIK motif forms a hydrogen
bond with Q343, a residue within the unusual activation loop
helix, rather than ion pairing with the canonical helix aC gluta-
mate, E239. Both the Q343A and E239A mutant forms of
MLKL retained ATP binding capacity (Figures 2D and S2B–
S2D). This indicates that ATP binding does not result from a
conformational change that repositions E239 of helix aC to
interact with K219 and that Q343 plays an auxiliary, rather than
an obligate, role in positioning K219 for ATP binding.
We further explored the relationship between MLKL and RIP
kinases in necroptosis by using biochemical techniques.
Although we did not detect an interaction between MLKL immu-Imnoprecipitated from mouse dermal fibroblasts (MDFs) and
endogenous RIPK1 or RIPK3 (Figure S2E) or between recombi-
nant MLKL and RIPK3 in isothermal titration calorimetry experi-
ments (not shown), recombinant RIPK3 kinase domain robustly
phosphorylated the MLKL pseudokinase domain within 5 min
of initiating an in vitro g-[32P]ATP kinase assay (Figure 2E). The
MLKL pseudokinase domain did not autophosphorylate (lanes
2 and 7, autoradiograph Figure 2E), consistent with its predicted
lack of catalytic activity. In control experiments with recombinant
RIPK3 harboring the kinase-inactivating mutation, D143N,
expressed and purified in the same manner as wild-type
RIPK3, we observed no MLKL phosphorylation (Figure S2F),
demonstrating that RIPK3 rather than a trace contaminant medi-
ates MLKL phosphorylation. By using mass spectrometry, we
identified S345, S347, and T349 within the MLKL activation
loop as the sites of RIPK3 phosphorylation (Figures 2F and
S2G–S2I). These data imply a transient substrate:kinase interac-
tion between MLKL and RIPK3.
MLKL Is Required for Necroptosis
To explore the physiological functions of MLKL, we generated
Mlkl-deficient mice. A targeting vector was constructed for gen-
eration of a modifiedMlkl allele via homologous recombination in
C57BL/6 embryonic stem cells (ESCs) (Figure 3A), allowing Cre-
dependent deletion of exon 3. Chimeric mice were generated
from an ESC clone bearing the targeted locus and heterozygous
offspring were bred to deleter cre-expressing mice (Schwenk
et al., 1995). Intercrosses of mice heterozygous for the cre-
deleted Mlkl allele (Mlkl) yielded mice of each of the three
expected genotypes in Mendelian ratios (21% Mlkl+/+, 50%
Mlkl+/, 29% Mlkl/, n = 24). Immunoblots of protein extracts
from a range of organs demonstrated that MLKL was readily
detectable in all organs, except the brain, in wild-type mice,
with particularly high levels evident in the bone marrow. MLKL
protein was absent in all tissues of homozygous mutant mice,
verifying functional deletion of the Mlkl gene (Figure 3B).
Mlkl/ mice appeared outwardly indistinguishable from their
heterozygous and wild-type littermates and histological exami-
nation of their major organs revealed no abnormalities. Periph-
eral blood cell numbers in Mlkl/ mice were within normal
ranges and enumeration of myeloid progenitor cells by colony
formation in semisolid medium revealed no numerical or
morphological anomalies in colonies grown from either the
bone marrow or spleen (Table S3). The number of cells in the lin-
eageSca-1+c-Kit+ (LSK) fraction of the bone marrow, which
contains the hematopoietic stem cells, was also normal in
Mlkl/mice (Figure S3A). In competitive transplantation assays,
Mlkl/ stem cells were able to compete as effectively as their
wild-type counterparts for long-term reconstitution of the
hematopoietic system of myeloablated transplant recipients
(Figure S3B).
In siRNA experiments, MLKL has recently been implicated in
TNF-induced necroptosis (Sun et al., 2012; Zhao et al., 2012).
Consistent with this observation, we found that Mlkl/ mouse
dermal fibroblasts (MDFs), mouse embryonic fibroblasts
(MEFs), and bone-marrow-derived macrophages (BMDMs)
were resistant to necroptosis induced by the combination of
TNF (T), Smac-mimetic (S), and the caspase-inhibitor QVD-
OPH (Q), in clear contrast to their wild-type counterparts (TSQmunity 39, 443–453, September 19, 2013 ª2013 Elsevier Inc. 445
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Figure 2. Recombinant MLKL Binds ATP In Vitro and Is a Catalytically Inactive Substrate of RIPK3
(A) Nucleotide binding by His6-tagged wild-type MLKL pseudokinase domain in the presence or absence of Mn
2+ or Mg2+ was determined with a thermal stability
shift assay. The plot is representative of three independent experiments.
(B) A bar graph analysis of the data presented in (A) (as described in Experimental Procedures).
(C and D) Thermal stability shifts measured for K219M (C) and Q343A (D) mutant forms of the MLKL pseudokinase domain in the presence or absence of
nucleotides and cations. Each plot is representative of at least two independent experiments. Corresponding thermal stability curves are shown in Figure S2.
(E) Recombinant MLKL pseudokinase domain (125 ng/ml) was subjected to g-[32P]ATP kinase assays in the presence or absence of increasing concentrations of
recombinant GST-RIPK3 kinase domain. Control experiments performed with recombinant RIPK3 harboring the inactivating mutation D143N are shown in
Figure S2F. Data shown are representative of three independent experiments. BSA was added as a carrier protein (100 ng/ml).
(F) S345, S347, and T349 in the MLKL activation loop were phosphorylated by RIPK3 in in vitro kinase assays. Cartoon of MLKL pseudoactive site (drawn in the
same orientation as in Figures 1B and 1C); red spheres represent oxygen atoms that are phosphorylated. See Figures S2G–S2I.
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MLKL Acts as a Molecular Switch in Necroptosistreatment, Figures 4A–4C and S4). Importantly, reconstitution of
full-length MLKL via an inducible lentiviral expression vector
restored the sensitivity ofMlkl/MDFs to TNF-induced necrop-
tosis (Figures 4D–4F).
MLKL Pseudoactive Site Mutants Induce Necroptosis in
the Absence of Exogenous Stimuli and Independently of
RIPK3 Activity
The crystal structure of MLKL revealed an unusual organization
of residues in the pseudoactive site. In particular, the atypical
activation loop helix residue Q343 coordinates the conventional446 Immunity 39, 443–453, September 19, 2013 ª2013 Elsevier Inc.ATP binding residue K219 (Figure 1B). We therefore sought to
establish the role of Q343 and its interactor, the key ATP-binding
lysine K219, in vivo.
Induced expression of K219M MLKL restored normal sensi-
tivity to TSQ-induced necroptosis in Mlkl/ MDFs (Figure 5A).
Because the K219M mutant was unable to bind ATP (Figures
2C and S2A), this result demonstrates that ATP binding is
dispensable for MLKL-dependent necroptosis. Interestingly,
there was also an indication of increased cell death in theMlkl/
MDFs when expression of the K219M mutant was induced in
the absence of other stimuli, and this was even more striking in
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Figure 4. Sensitivity of Mlkl–/– MDFs to Necroptotic Stimuli
(A) MDF cell lines derived from wild-type or Mlkl/ mice were treated with
necroptosis-inducing stimuli as indicated for 20 hr. Abbreviations are as fol-
lows: T, TNF; S, Smac-mimetic; N, Necrostatin-1; Q, QVD-OPH. Cell death
was measured by enumerating PI permeable cells with flow cytometry.
(B–E) Representative flow cytometry plots of wild-type MDFs (B), Mlkl/
MDFs (C), and Mlkl/ MDFs reconstituted with inducible wild-type MLKL off
(D) or on (E) stimulated by TSQ treatment and stained with PI. Data are
representative of at least three biological replicates.
(F) TSQ-treated Mlkl/ MDFs inducibly expressing (white bars) or not
expressing (black bars) MLKL. UT, untreated.
Data are plotted as the mean ± SD of at least three biological replicates. See
also Figure S4.
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Figure 3. Functional Deletion of the Mlkl Gene in Mice
(A) Gene targeting strategy for the generation of MLKL-deficient mice. The
location of exons is indicated by raised, numbered boxes. A targeting vector, in
which an frt-flanked neomycin resistance cassette was inserted in intron 3 of
the Mlkl genomic locus along with loxP sites upstream of exon 3 and imme-
diately downstream of the resistance cassette, was used to generate the
targeted locus in ESCs via homologous recombination. Mice bearing the tar-
geted locus were bred with deleter cre-expressing mice (Schwenk et al., 1995)
to generate mice heterozygous for the recombined D-exon 3 locus (Mlkl+/
mice). These heterozygous Mlkl+/ mice were intercrossed to produce
homozygous Mlkl/ mice. See also Figure S3 and Table S3.
(B) Immunoblot for MLKL protein on extracts of tissues from twoMlkl/ (/)
mice and one wild-type (+/+) mouse. Wild-type (+/+) immunoblots are repre-
sentative of three independent experiments. After probing for MLKL, blots
were stripped and reprobed with antibodies to HSP70 (loading control, bot-
tom). Molecular weight markers (kDa) are indicated at the left.
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MLKL Acts as a Molecular Switch in Necroptosiswild-type MDFs induced to express K219M MLKL (Figure 5B).
We obtained similar, but more pronounced, results with a
Q343A mutant MLKL, which cannot hydrogen bond with K219,
because inducible expression of this mutant caused significant
cell death in both Mlkl/ (Figure 5C) and wild-type (Figure 5D)
MDFs. Immunoblot analysis confirmed that expression of the
K219M and Q343A MLKL mutants was comparable to that of in-
ducibly expressed wild-type MLKL (Figure S5D), which did not
induce TSQ-independent cell death. This demonstrates that per-
turbations to the pseudoactive site, rather than disparate
expression levels, underlie the constitutive necroptosis-inducing
activity of these mutants. Enforced overexpression of certain
proteins can cause apoptosis. It was therefore possible thatImthe death induced by enforced expression of the MLKL mutants
might be different from necroptotic death induced by stimulation
with TSQ. The broad-spectrum caspase inhibitor QVD-OPH hadmunity 39, 443–453, September 19, 2013 ª2013 Elsevier Inc. 447
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Figure 5. Cell Death of Mlkl–/–, Wild-Type, and Ripk3–/– MDFs Inducibly Expressing Pseudoactive Site Mutants of MLKL
(A and B) A K219Mmutant MLKL was inducibly expressed inMlkl/MDFs (A) or wild-type MDFs (B) ± TS (apoptotic stimulus) or TSQ (necroptotic stimulus) and
cell death quantitated by PI staining and flow cytometry. Abbreviations are as follows: UT, untreated; T, TNF; S, Smac-mimetic; Q, QVD-OPH.
(C and D) A Q343A mutant MLKL was inducibly expressed in Mlkl/ (C) or wild-type MDFs (D) and treated and assayed as in (A).
(E) A Q343A mutant MLKL was inducibly expressed in Mlkl/ MDFs ± QVD-OPH (Q), Nec-1 (N), or QVD-OPH plus Nec-1 (QN).
(F–H) Ripk3/MDFs with inducible wild-type (F), K219M (G), or Q343A (H) MLKL ± TS or TSQ were stained with PI staining and cell death quantitated by flow
cytometry.
(I) The phosphomimetic S345DmutantMLKLwas inducibly expressed inwild-typeMDFs and death in the presence or absence of apoptotic or necroptotic stimuli
quantitated by PI staining and flow cytometry.
(J and K) The mouse counterparts of MLKL mutations identified in human stomach cancer, F385I (J) and L280P MLKL (K), were inducibly expressed in Mlkl/
MDFs and their sensitivity to apoptotic and necroptotic stimuli examined. Positions of these mutations within the MLKL structure are shown in Figure S1E.
In all panels, cell lines were treated as indicated and 24 hr later PI-positive cells were quantitated via flow cytometry. The results represent the mean ± SD from
three independently derived MDF cell lines, each tested one to three times. See also Figure S5.
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Figure 6. Sensitivity of Wild-Type MEFs to Necroptotic Stimuli after
shRNA Knockdown of PGAM5
(A) Wild-type MEFs stably transfected with doxycycline-inducible shRNAs
targeting PGAM5 were treated with doxycycline and after 72 hr immunoblot
was used to measure knockdown efficiency compared to a rat CD8 shRNA
control. Two independent clones were used in these studies. HSP70 was used
as a loading control.
(B) Wild-type MEFs stably expressing shRNAs against PGAM5 were treated
with 100 ng/ml TNF (T), 500 nM Smac mimetic (S), and 25 mM QVD (Q) or left
untreated (UT), as indicated. Cell viability was determined after 24 hr of
treatment by PI staining and flow cytometry. Data are represented as the
mean ± SEM of at least three independent experiments.
Parallel experiments with L929 cells are shown in Figure S6.
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MLKL Acts as a Molecular Switch in Necroptosisno effect on Q343A mutant MLKL-induced cell death, demon-
strating that overexpression of this mutant does not cause
apoptosis (Figure 5E). RIPK1would be expected to act upstream
of MLKL in necroptosis signaling and, accordingly, the RIPK1
inhibitor Nec-1 had no effect on Q343A mutant MLKL-induced
cell killing either alone or in the presence of the caspase inhibitor
QVD-OPH (Figure 5E), although these inhibitors were functional
in blocking TSQ-induced necroptosis and TS-induced apoptosis
in these cells (Figure S5A). The small amount of cell death
caused by induced expression of wild-type MLKL in Mlkl/
MDFs was likewise unaffected by QVD-OPH or Nec-1
(Figure S5B), despite the fact that these inhibitors blocked
TSQ-induced necroptosis and TNF/cycloheximide-induced
apoptosis in these same cells (Figure S5C).
During TSQ-induced necroptosis, MLKL is thought to act
downstream of RIPK3 (Sun et al., 2012; Zhao et al., 2012). As
previously described for RIPK3-deficient cells (He et al., 2009),
ourRipk3/MDFswere insensitive to TSQ-induced necroptosis
(Figure 5F). Consistent with the notion that RIPK3 acts upstream
of MLKL, inducible overexpression of wild-type MLKL was
unable to restore sensitivity of these Ripk3/ fibroblasts to nec-
roptotic stimuli (Figure 5F). In contrast, but consistent with the
notion that MLKL acts downstream of RIPK3, expression of theImK219M or Q343Amutant forms ofMLKL caused substantial nec-
roptosis in RIPK3-deficient cells in the absence of any additional
stimulus (Figures 5G and 5H). We then examined whether substi-
tution of the MLKL activation loop residue S345 with Asp, to
mimic phosphorylation by RIPK3 conferred a similar phenotype
on MDFs as the pseudoactive site mutants. Indeed, S345D
mutant MLKL expression in wild-type (Figure 5I) and Mlkl/
(not shown) MDFs led to cell death in the absence of necroptotic
stimuli. These data suggest that the K219M and Q343A pseu-
doactive site mutations cause a conformational change within
MLKL that mimics RIPK3-mediated activation of MLKL to induce
spontaneous, RIPK3-independent necroptosis.
Two mutations in highly conserved residues located within the
C-lobe of the MLKL pseudokinase domain, F398I and L291P
(F385 and L280 in mouse MLKL) (Figures S1D and S1E), have
been identified in human stomach adenocarcinoma samples
(Forbes et al., 2008). Although the F385I MLKL mutant showed
wild-type activity when inducibly expressed in Mlkl/ cells
treated with TSQ (Figure 5J), the L280P MLKL mutant failed to
restore sensitivity to this necroptotic stimulus (Figure 5K),
despite being expressed at comparable levels to endogenous
MLKL (Figure S5D). This suggests that, owing to a likely struc-
tural perturbation within the C-lobe of the MLKL pseudokinase
domain (Figure S1E), L280P represents a loss-of-function muta-
tion of MLKL.
The Mitochondrial Protein PGAM5 Is Dispensable for
RIPK3-MLKL-Mediated Necroptosis
The mitochondrial phosphatase PGAM5 was reported to be a
critical downstream effector both of necroptosis induced by
TNFR1 > RIPK1 > RIPK3 > MLKL signaling and of necroptosis
induced by cytotoxic stimuli that are independent of these signal
transducers, such as H2O2 or ionomycin (Wang et al., 2012). We
sought to further define the role of PGAM5 in the RIPK3 > MLKL
necroptosis signaling pathway by knocking down expression
of PGAM5 by using shRNA in wild-type MEFs and L929 fibro-
blastoid cells (Figures 6A, S6A, and S6B). Intriguingly, cells in
which a PGAM5 shRNA or a nonsilencing control shRNA were
expressed were equally susceptible to TSQ-induced necropto-
sis (Figures 6B and S6C). This suggests that additional or alter-
native pathways must operate in RIPK3 > MLKL-mediated
necroptosis.
DISCUSSION
Necroptosis is a form of programmed cell death that occurs
when apoptosis and caspase activity are inhibited. Because
this constitutes a mechanism that may allow elimination of path-
ogens that are able to subvert classical apoptotic cell death or as
a failsafe in other situations where the preferred apoptosis
pathway fails, there has been considerable interest in defining
the molecular regulators of necroptosis and their mechanisms
of action. Recent evidence suggests that necroptosis is depen-
dent on the RIP kinases RIPK1 and RIPK3 (Cho et al., 2009; Deg-
terev et al., 2005; Duprez et al., 2011; He et al., 2009); the MLKL
pseudokinase has also been implicated as a keymediator down-
stream of RIPK3 (Sun et al., 2012; Zhao et al., 2012). To define
the function of MLKL in a physiological context, we generated
mice lacking a functional Mlkl gene. Although devoid ofmunity 39, 443–453, September 19, 2013 ª2013 Elsevier Inc. 449
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of stressMlkl/mice were healthy and fertile, with no apparent
pathological abnormalities or hematological disturbance. Cells
derived from Mlkl/ mice were, however, completely resistant
to TSQ-induced necroptosis, and normal sensitivity could be
restored upon reconstitution of MLKL expression. This demon-
strates an essential role for MLKL in necroptosis. This contrasted
with the absence of any effect on the sensitivity of cells to nec-
roptosis upon shRNA-mediated reduction in the expression of
the phosphatase PGAM5. This suggests that pathways acting
in a manner redundant with, or instead of, PGAM5 are critical
for necroptosis, at least within the cells studied here.
The lack of an overt phenotype in unstressed Mlkl/ mice in
our study is consistent with a recent report describingMlkl-defi-
cient mice generated by the TALEN approach (Wu et al., 2013)
and is similar to observations made with mice lacking RIPK3
(Newton et al., 2004), a critical regulator of TNF-induced necrop-
tosis thought to act upstream of MLKL. RIPK3-deficient mice
were, however, reported to show abnormal inflammatory
responses during vaccinia virus infection (Cho et al., 2009), cer-
ulein-induced acute pancreatitis (He et al., 2009), and TNF
administration (Duprez et al., 2011). Together, these data show
that RIPK3 is required for induction of necroptosis and suggest
that RIPK3-MLKL-driven cell death is more important in
response to the challenges of infection or pathological inflam-
mation than in steady-state homeostasis. Although our data
clearly implicate MLKL as a crucial effector of TNF-induced nec-
roptotic signaling, a recent study showed that MLKL contributes
to inflammasome activation (Kang et al., 2013), raising the
exciting possibility that MLKL, like RIPK3, may serve important
functions in other signaling pathways. A potential role for
MLKL in neoplastic disease was raised by the identification of
mutations in highly conserved residues within the MLKL pseu-
dokinase domain in human stomach adenocarcinoma (Forbes
et al., 2008). Our observation that one of these mutations,
MLKL L280P, lacks activity in MLKL-induced necroptosis
assays strengthens this notion and implies that further investiga-
tion of MLKL as a potential tumor suppressor in some cancer
contexts is warranted.
To better define the molecular mechanism by which MLKL
acts, we solved the crystal structure of full-length mouse MLKL
to 2.6 A˚ resolution. This structure revealed MLKL to be
composed of an N-terminal four-helix bundle braced to the
C-terminal pseudokinase domain via a two helix linker. Of partic-
ular interest, the pseudokinase domain contained an atypical he-
lix in the activation loop that packed against the N-lobe aC helix.
This prevents the formation of the canonical ionic bond between
the lysine of the VAIK motif (K219) and the helix aC glutamate
(E239), an interaction that is synonymous with an active protein
kinase conformation. In place of the helix aC glutamate, the res-
idue Q343 that is within the unusual activation loop helix
hydrogen bonds K219. An examination of MLKL amino acid
sequences among orthologs revealed that K219 is almost uni-
versally conserved and that Q343 is present as Gln or Glu (Fig-
ure S1D). The one exception to the conservation of K219 was
in O. garnettii MLKL where a charge reversal was present: the
K219 position was substituted with Glu and the Q343 position
with Lys. Collectively, these data suggest that orthologs of
K219 and Q343 serve important functions in MLKL.450 Immunity 39, 443–453, September 19, 2013 ª2013 Elsevier Inc.As predicted from the crystal structure, the MLKL pseudoki-
nase domain was capable of nucleotide binding, though only in
the absence of Mg2+ and Mn2+. As anticipated, nucleotide bind-
ing was lost upon mutation of the canonical ATP-binding residue
K219. Although the VAIKmotif Lys is typically thought of as a cat-
alytic, rather than ATP-binding, residue in active protein kinases
(Carrera et al., 1993), recent studies suggest that pseudokinase
domains have evolved mechanisms of ATP binding divergent
from bona fide protein kinases. For example, mutation of the
VAIK motif in the pseudokinase domain of HSER/GC-C has pre-
viously been shown to abrogate ATP binding (Jaleel et al., 2006).
Consistent with the notion that pseudokinase domains have
evolved unconventional ATP binding modes, we observed that
Mg2+ and Mn2+ thwarted ATP binding by MLKL. Because diva-
lent cations play an essential role in catalyzing the kinase
reaction, it is therefore unlikely that MLKL will function as a cata-
lytically active protein kinase. Indeed,MLKL at very high concen-
trations (125 ng/ml) exhibited no autophosphorylation in in vitro
kinase assays, an observation consistent with a previous report
(Sun et al., 2012), but was a substrate of recombinant RIPK3 in
the same in vitro kinase assays. Coimmunoprecipitation and
isothermal titration calorimetry studies failed to detect a stable
complex containing RIPK3 and MLKL, suggesting that their
interaction was transient and typical of an enzyme:substrate
complex. Thus, we propose that MLKL, activated by RIPK3-
mediated phosphorylation, is likely to serve as a substrate of
the necrosome rather than as a catalytically active kinase.
Indeed, the K219M mutant form of MLKL that cannot bind ATP
restored normal sensitivity to necroptotic stimuli (TSQ) in
Mlkl/ MDFs. Although one report has suggested that MLKL
can function as a kinase (Zhao et al., 2012), these studies used
MLKL immunoprecipitated from 293T cells, making it possible
that the weak activity they observed was from a kinase that
had coprecipitated with MLKL. Our data support the idea that
pseudokinases play important, nonenzymatic roles in cellular
signaling and demonstrate that neither ATP binding nor kinase
activity is crucial for MLKL function in necroptosis.
Inducible expression of the K219M MLKL mutant triggered
necroptosis in MDFs in the absence of TSQ treatment. This
constitutive necroptosis-inducing activity was recapitulated by
a mutation perturbing Q343, the binding partner of K219 in the
MLKL pseudoactive site. The absence of definitive markers
makes it difficult to conclude that the death induced by Q343A
or K219M mutant forms of MLKL is definitively necroptotic, but
this death could not be blocked by inhibition of caspases or
RIPK1. Moreover, although inducible expression of wild-type
MLKL did not restore sensitivity to necroptotic stimuli in
Ripk3/ MDFs, expression of comparable levels of K219M or
Q343A mutant forms of MLKL killed these Ripk3/ MDFs in
the absence of any stimuli. These data are consistent with the
notion that the K219M and Q343A mutations subvert the need
for RIPK3 phosphorylation to activate the necroptotic activity
of MLKL. Based on these observations, we propose that struc-
tural changes in the MLKL activation loop are normally induced
by RIPK3-mediated phosphorylation, which in turn alter the
conformation of the MLKL pseudoactive site to cause necropto-
sis. This is further supported by the proximity of Q343 to the
MLKL activation loop residues that we identified as substrates
of RIPK3 phosphorylation (S345, S347, and T349) and the
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induce necroptosis signaling in the absence of stimuli. These
data support a model in which the MLKL mutants K219M and
Q343A emulate the activation loop perturbations usually induced
by RIPK3-mediated phosphorylation, circumventing the require-
ment for RIPK3 phosphorylation and allowing spontaneous
necroptosis. Thus, MLKL phosphorylation by RIPK3 constitutes
a critical checkpoint in necroptosis signaling.
EXPERIMENTAL PROCEDURES
Expression Constructs
The mouse MLKL cDNA encoding residues 1–464 was PCR amplified from a
reverse-transcribed cDNA library derived from G1ME cells (Stachura et al.,
2006) and ligated into pBlueScript SK or obtained as a synthetic DNA in which
several restriction sites were eliminated by silent substitutions (DNA2.0).
Mutations were introduced into the MLKL cDNA by oligonucleotide-directed
PCR mutagenesis. DNA oligonucleotides encoding shRNA sequences target-
ing PGAM5 were designed and cloned into the dox-inducible lentiviral expres-
sion vector FH1tUTG. Details can be found in the Supplemental Experimental
Procedures.
Recombinant Protein Expression and Purification
cDNAs encoding Mus musculus MLKL 1–464 or 179–464 with and without
mutations were cloned into the pFastBac HTb vector (Life Technologies). A
cDNA encoding mouse RIPK3 kinase domain was cloned into either pFastBac
HTb or a derivative of pFastBac1 incorporating an N-terminal GST tag. For
details of expression and purification methods, see Supplemental Experi-
mental Procedures. Selenomethionine incorporation into MLKL 1–464 for
crystallographic phasing was based on a published method (Cronin et al.,
2007), with further details in Supplemental Experimental Procedures.
Crystallization and Structure Determination
Full-length MLKL was concentrated to 5 mg/ml and subjected to robotic crys-
tal trials (C3 Facility, CSIRO). Initial screens yielded small needles that were
optimized to produce larger needles as outlined in Supplemental Experi-
mental Procedures. X-ray diffraction data were collected at the Australian
Synchrotron beamline MX2 at 100K. Data were processed with HKL2000
(Otwinowski and Minor, 1997) and the structure solved by SAD with
autoSHARP (Vonrhein et al., 2007) with data collected from crystals soaked
in 2 mM UO2(NO3)2 before freezing. Initial building with Arp/Warp (Langer
et al., 2008) and refinement with REFMAC5 (Murshudov et al., 2011) provided
regions of model and maps sufficient in detail to identify the pseudokinase re-
gion. Subsequent rounds of building with COOT (Emsley et al., 2010) and
refinement with Phenix (Adams et al., 2010), guided in part by comparison
to published kinase structures, provided an early model that was subse-
quently refined against higher-resolution native data. Building of the novel
N-terminal domain was further assisted by the identification of methionine
residues in anomalous difference maps produced in Phenix (Adams et al.,
2010) with data from selenomethionine-incorporated crystals. Small-angle
X-ray scattering data were collected as described in the Supplemental Exper-
imental Procedures with parameters shown in Table S2. All structure cartoons
were drawn with Pymol.
Thermal Shift Assay for Nucleotide Binding
The thermal stability shift assay was conducted with a Corbett Real Time PCR
machine as detailed in the Supplemental Experimental Procedures.
Generation of MLKL-Deficient Mice
Homologous recombination in ESCs was used to generate a conditionally tar-
geted Mlkl locus with exon 3 flanked by loxP sites. Additional details and the
methods used to generate homozygous D-exon 3 Mlkl/ mice on an inbred
C57BL/6 background, as well as PCR-based genotyping, can be found in
the Supplemental Experimental Procedures. Animal experiments were per-
formed according to protocols approved by the Walter and Eliza Hall Institute
of Medical Research Animal Ethics Committee.ImHistological and Hematological Analysis
Histological and hematological analyses of Mlkl/ mice were performed
according to published methods (Alexander et al., 1996), with additional
details provided in Supplemental Experimental Procedures.
Reagents and Antibodies
Recombinant hTNF-Fc was produced in-house as described (Bossen et al.,
2006). Puromycin, doxycycline, necrostatin-1, and cycloheximide were pur-
chased from Sigma-Aldrich. The Smac mimetic Compound A has been
described previously (Vince et al., 2007). QVD-OPH was purchased from
R&D Systems. A monoclonal rat anti-mouse MLKL antibody (clone 3H1) was
raised in-house by the Walter and Eliza Hall Institute Monoclonal Facility by
immunizing Wistar rats with the peptide CQPASWQQEDRQDAEED, conju-
gated to keyhole limpet hemocyanin. Anti-b-actin antibody was purchased
from Sigma Aldrich; anti-HSP70 antibody was purchased from Santa Cruz
or kindly provided by R. Anderson, Peter MacCallumCancer Research Centre;
rabbit polyclonal anti-PGAM5 antibody was kindly provided by Z. Wang, UT
Southwestern Medical Center at Dallas (Wang et al., 2012); rabbit anti-
RIPK3 antibody was purchased from ProSci; and mouse anti-RIPK1 antibody
was purchased from BD Biosciences. HRP-conjugated secondary antibodies
were purchased from GE Healthcare and Jackson Immunoresearch. Immuno-
precipitations and immunoblot analysis were performed as described in the
Supplemental Experimental Procedures.
Cell Lines and Cell Death Assays
Mouse embryonic fibroblasts (MEFs) derived from Mlkl/ or wild-type mice
were generated from E14.5 embryos and immortalized with SV40 large T
antigen. MEFs, HEK293T, and L929 cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 8%–10% fetal calf
serum (FCS) and 5 mg/ml puromycin for lines stably transduced with inducible
expression constructs for MLKL. Mouse dermal fibroblasts and mouse
embryonic fibroblasts were isolated from three Mlkl/ mice and three con-
genic wild-type mice and then immortalized by SV40 large T antigen to
generate three biologically independent cell lines. Immortalized MDFs were
similarly prepared from three Ripk3/ mice and congenic wild-type mice.
Cell death assays were carried out in 24-well plates, seeding 1 3 105 cells
per well. Cells attached over 4 hr in the presence of 10 ng/ml doxycycline
were then treated with assorted combinations of cycloheximide (250 ng/ml),
necrostatin (50 mM), and QVD-OPH (5 mM) 30 min prior to addition of TNF
(100 ng/ml) and Smac mimetic (500 nM). After 24 hr, cells were harvested
and PI-positive cells (100 ng/ml) were quantified with a BD FACSCalibur
flow cytometer. For assessment of the effects of PGAM5 knockdown, MEFs
or L929 cells were treated with doxycycline to induce the expression of the
short hairpins. After 48 hr, cells were seeded into 24-well plates at 5 3 104
cells per well and the following day were treated with TNF, Smac mimetic,
and QVD-OPH. After 24 hr, adherent cells were stained with PI and assessed
by flow cytometry. BMDM cell suspensions from bone marrow were cultured
for 6 days in DME supplemented with 10% FCS and 20% L929 conditioned
medium. At day 6 the resulting BMDMs were plated at 5 3 105 cells per
well in a 24-well plate and the following day were treated with TNF, Smac
mimetic, and QVD-OPH. After 24 hr, adherent cells were stained with PI
and assessed by flow cytometry.
Statistical Analyses
Error bars represent mean ± SD (Figures 4 and 5) or mean ± SEM (Figure 6).
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The atomic coordinates and structure factors for MLKL (PDB ID code 4BTF)
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Structural Bioinformatics, Rutgers University (http://www.rcsb.org).
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